Post-authorisation efficacy studies for medicines

This regulation establishes the specific conditions under which the European Commission may require pharmaceutical companies to conduct efficacy studies after a medicine has already been authorized for market. These studies ensure that medicines continue to work as intended and provide the necessary clinical evidence for their ongoing use.

This affects pharmaceutical manufacturers and regulatory bodies. It ensures that patients and healthcare providers have updated, evidence-based information on the effectiveness of medicines throughout their lifecycle.